The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMDS 2025 | Advances in the treatment of LR-MDS: luspatercept combinations, the use of imetelstat & more
In this discussion, experts Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, Mikkael Sekeres, MD, MS, Sylvester Comprehensive Cancer Center, Miami, FL, and Lionel Ades, MD, PhD, Hospital Saint-Louis, Paris, France, discuss recent advances in the treatment and management of lower-risk myelodysplastic syndromes (LR-MDS). They highlight the COMBOLA study (NCT05181735) and discuss the use of imetelstat in this patient population. This discussion took place at the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
